Recordati S.p.A. | Income Statement

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
Sales/Revenue
942
987
1,048
1,154
1,288
Cost of Goods Sold (COGS) incl. D&A
327
327
335
361
383
Gross Income
614
660
712
793
905
SG&A Expense
404
425
429
453
497
EBIT
209
234
284
340
409
Unusual Expense
14
4
4
13
1
Non Operating Income/Expense
1
3
2
2
5
Interest Expense
14
17
12
12
14
Pretax Income
181
215
265
317
389
Income Tax
47
54
67
80
100
Consolidated Net Income
134
161
199
237
289
Net Income
134
161
199
237
289
Net Income After Extraordinaries
134
161
199
237
289
Net Income Available to Common
134
161
199
237
289
EPS (Basic)
0.66
0.79
0.97
1.15
1.40
Basic Shares Outstanding
202
204
205
206
207
EPS (Diluted)
0.63
0.77
0.95
1.13
1.38
Diluted Shares Outstanding
212
209
209
209
209
EBITDA
244
277
322
378
457
Other Operating Expense
1
1
-
-
-
Non-Operating Interest Income
-
4
-
-
-
Minority Interest Expense
-
-
-
-
-

About Recordati

View Profile
Address
Via Matteo Civitali, 1
Milan Milan 20148
Italy
Employees -
Website http://www.recordati.it
Updated 09/14/2018
Recordati SpA engages in the research, development, manufacturing and marketing of pharmaceuticals. It operates through two segments: Pharmaceutical and Rare Diseases. The Pharmaceutical segment offers prescription and over-the-counter products as well as chemical syntheses, intermediates, and active ingredients for its proprietary and licensed brands.